adding standalone BPC-157 or TB-500 on top double-counts those peptides and muddies attribution of any effect
While the past decade was shaped by GLP-1 mono-agonists and most recently by dual GIP/GLP-1 agonists such as tirzepatide, cagrilintide expands the repertoire with the amylin pathway
If youre also on blood-thinning medications, the risk multiplies
Researched effects In a diet-induced-obese mouse study (Neelakantan et al., Biochemical Pharmacology, 2018), subcutaneous 5-Amino-1MQ (20 mg/kg, three times daily, roughly 11 days) produced about 5.1% body-weight loss versus continued weight gain in untreated controls, roughly 35% less epididymal white fat mass, smaller adipocytes, lower plasma cholesterol, and improved glucose tolerance, with no reported change in food intake and no observed adverse effects in the mice